SELUMETINIB SULPHATE

Selumetinib sulphate is a MEK1/2 inhibitor used for NF1-related plexiform neurofibromas. It blocks MAPK signaling. Side effects include diarrhea, rash, cardiomyopathy, ocular changes, and elevated CPK. Only GMP materials will be supplied, logistics all according to GDP.

Category:

Product Description


Mechanism of Action

SELUMETINIB SULPHATE exhibits a high-dimensional biochemical activity profile integrating catalyticdomain modulation, multiaxis signalling disruption, mitochondrialnetwork recalibration, ionflux redistribution, redoxstate restructuring, cytoskeletal remodelling, membraneelectrochemical modulation and transcriptionfactor pathway reprogramming. Its molecular architecture supports highaffinity interaction with catalytic residues, allosteric regulators, hydrophobic receptor pockets, transmembrane helices, nucleotidebinding pockets, redoxbuffer matrices and polymeric scaffolding complexesgranting broad mechanistic influence across metabolic, genomic, electrophysiological and structural systems.

SELUMETINIB SULPHATE may reorganise phosphorylationflow geometry across ERK/MAPK/JNK/p38 cascades, alter PI3KAKT survival signalling, shift Gprotein coupling patterns, redistribute Ca²⁺ microdomains, reshape IP/DAG signalling topology, and recalibrate cAMPPKA amplitude dynamics. Mitochondrial impacts include ETCcomplex activation shifts, ATP/ADP turnover modulation, ROSthreshold displacement, mitochondrialmembrane potential polarity changes and ERmitochondrial stresssignal coupling, making the compound highly valuable for mechanistic and translational research models.

Advanced

  • Kinomescale catalyticcascade mapping and interference modelling
  • Ultraresolution ligand docking and conformationaltransition analysis
  • UPR/ERstress, mitophagy, autophagy and oxidativestress crossnetwork characterisation
  • Multiomics system reconstruction (RNAseq, metabolomics, proteomics, phosphoproteomics)
  • Cytoskeletal mechanics and polymerturnover modelling
  • Cellfate mapping across apoptosis, necroptosis, ferroptosis, pyroptosis and parthanatos
  • Machinelearning driven SAR/QSAR molecularperformance prediction

Toxicodynamics & Cellular Hazard Spectrum

  • ROS hyperaccumulation and antioxidant-system collapse
  • Mitochondrial fragmentation, ETC shutdown or hyperleak states
  • Severe Na⁺/K⁺/Ca²⁺ ionic-flux dysregulation
  • Cytoskeletal depolymerisation and membrane-integrity failure
  • NF-κB, STAT and IRF inflammatoryaxis hyperactivation
  • Engagement of multiaxis programmed-cell-death pathways
  • Epigenetic drift including methylation and acetylation imbalance

For expert laboratory research only not intended for biological or therapeutic exposure.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C17H17BrClFN4O7S

Molecular Weight

555.8 g/mol

CAS Number

943332-08-9

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

Selumetinib sulfate; 943332-08-9; AZD-6244 hydrogen sulfate; Selumetinib sulphate; AZD-6244 Hyd-Sulfate

IUPAC/Chemical Name

6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide;sulfuric acid

InChl Key

GRKFGZYYYYISDX-UHFFFAOYSA-N

InChl Code

InChI=1S/C17H15BrClFN4O3.H2O4S/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19;1-5(2,3)4/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26);(H2,1,2,3,4)

References

https://pubchem.ncbi.nlm.nih.gov/compound/16214875;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download